207_Combined course Presentations

Conclusion

• Biological basis for combining RT with check-point inhibitors

• In mice models there seems to be synergy

• Different toxicity profile

• Apparently not synergy re. side effects

• Trials are ongoing

• No immuno-RT treatments can be considered standard – everything should be done in controlled trials